EcoDrugPlus

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSHCOG00000005394
Gene Symbol: CHRM5
3 Cross references
189 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSHCOG00000020977
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSHCOG00000008218
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSHCOG00000020813
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSHCOG00000016895
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSHCOG00000014720
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSHCOG00000006002
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSHCOG00000007086
Gene Symbol: LOC109528433
3 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSHCOG00000007273
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSHCOG00000004634
Gene Symbol: LOC109519192
2 Cross references
215 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSHCOG00000017498
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSHCOG00000013269
Gene Symbol: LOC109531162
2 Cross references
277 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).